Litcius/Paper detail

613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial

Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, M.E. Elez Fernandez, F.J.S.M. Cruz, Lucjan Wyrwicz, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Elizabeth Calleja, L. Roby, Valentine Barboux, N. Caussé-Amellal, Josep Tabernero

2023Annals of Oncology10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBevacizumabInternal medicineRegimenPost-hoc analysisColorectal cancerSubgroup analysisOncologyRefractory (planetary science)GastroenterologyChemotherapyCancerConfidence intervalAstrobiologyPhysicsColorectal Cancer Treatments and StudiesCancer Treatment and PharmacologyGastric Cancer Management and Outcomes
613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial | Litcius